This is a working overview of LC-MS, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-09-24 and is reviewed periodically as new material appears.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Appearance | Off-white to pale yellow solid | Visual description varies with purity and source |
| Solubility | Soluble in DMSO and ethanol; poorly soluble in water | Organic stock solutions are common in research |
| Typical storage | -20 °C, desiccated, protected from light | Avoid repeated freeze-thaw cycles |
| Typical analytical method | LC-MS or HPLC-UV | Reference standards are needed for quantification |
| Molar mass | Approximately 437.9 g/mol | Calculated from the reported free-base formula |
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
The first Zaxbys was established in Statesboro, Georgia, in March 1990, near the Georgia Southern University campus, by childhood friends Zach McLeroy and Tony Townley; the first restaurant was known as "Zax" before becoming Zaxby's. The company's first restaurant outside of Georgia was opened in September 1994 in Bowling Green, Kentucky. In 2013, they opened locations in Utah, the first expansion outside of the southeastern United States. In 2022, Zaxbys appointed Bernard Acoca as its first non-founder CEO. Zach McLeroy remained as chairman, while Tony Townley exited the company following its acquisition by Goldman Sachs in November 2020. In 2024, Zaxbys announced expansion plans for 2025, including a store in Cambridge, Maryland, the first location in the state. More locations are slated to open along the Eastern Shore of Maryland in the coming years. As of 2025, Zaxbys had more than 970 locations throughout the U.S.
In this case the antibodies is produced externally in cultured cells and are delivered to the patient in the form of a drug. In mice expressing APP, both active and passive immunization of anti-Aβ antibodies has been shown to be effective in clearing plaques, and can improve cognitive function. Currently, there are two FDA approved antibody therapies for Alzheimer's disease, Aducanemab and Lecanemab. Aducanemab has received accelerated approval while Lecanemab has received full approval. Several clinical trials using passive and active immunization have been performed and some are on the way with expected results in a couple of years. The implementation of these drugs is often during the early onset of AD. One trial testing Foralumab seeks to determine if there is benefit in later stages of AD by reduction of brain inflammation. Other research and drug development for early intervention and AD prevention is ongoing. Examples of important mAb drugs that have been or are under evaluation for treatment of AD include Bapineuzumab, Solanezumab, Gautenerumab, Crenezumab, Aducanemab, Lecanemab and Donanemab.
A gonadotropin-releasing hormone antagonist (GnRH antagonist) is a GnRH modulator that blocks the GnRH receptor resulting in an immediate drop in gonadotropin (FSH, LH) secretion. GnRH antagonists are primarily used in IVF treatments to block natural ovulation.
After World War I, the victors settled border changes. The Treaty of Saint-Germain of 1919 ruled according to the 1915 London Pact, that the southern part of the Austrian crown land of Tyrol had to be ceded to the Kingdom of Italy, including the territory of the former Trent bishopric, roughly corresponding to the modern-day Trentino, as well as the south of the medieval Tyrol county, the present-day province of South Tyrol. Italy thus took control of the strategically important Alpine water divide at the Brenner Pass and over the south of Tyrol proper with its large German-speaking majority. Since 1949 both parts form the autonomous Italian Trentino-Alto Adige/Südtirol region. The northern part of Tyrol retained by the First Austrian Republic today forms the Austrian State of Tyrol with its East Tyrol exclave. In 1945 following World War II, Austrian attempts and South Tyrolean petitions to reunite South Tyrol with Austria were unsuccessful; Italy retained control. From 1972 onwards, the Italian Republic has granted further autonomy to the Trentino-Alto Adige/Südtirol region.
== Biological activity == Prodigiosin received renewed attention for its wide range of biological activities, including activities as antimalarial, antifungal, immunosuppressant, and antibiotic agents. It is perhaps best known for its capacity to trigger apoptosis of malignant cancer cells. The exact mechanism of this inhibition is highly complex and not entirely elucidated, but could involve multiple processes, including phosphatase inhibition, copper mediated cleavage of double stranded DNA, or disrupting the pH gradient through transmembrane transport of H+ and Cl- ions. As a result, prodigiosin is a highly promising drug lead, and is currently in preclinical phase study for pancreatic cancer treatment. Prodigiosin has recently been found to have excellent activity against stationary phase Borrelia burgdorferi, the causative agent of Lyme disease. Prodigiosin has been also reported to exhibit antimicrobial activity against Gram-positive bacteria including methicillin resistant Staphylococcus aureus (MRSA), Staphylococcus aureus, Enterococcus faecalis, as well as Gram-negative Escherichia coli, Vibrio vulnificus, Salmonella enterica. Although the exact mechanism of action is not completely understood, recent molecular docking studies show that prodigiosin may interact with fatty acid biosynthetic enzyme in bacteria. Prodigiosin is also found to act as algaecide against harmful algal bloom.
Sources: en.wikipedia.org
=== Cell cycle === TGF-β plays a crucial role in the regulation of the cell cycle by blocking progress through G1 phase. TGF-β causes synthesis of p15 and p21 proteins, which block the cyclin:CDK complex responsible for retinoblastoma protein (Rb) phosphorylation. Thus, TGF-β blocks advancement through the G1 phase of the cycle. In doing so, TGF-β suppresses expression of c-myc, a gene which is involved in G1 cell cycle progression.
Both specialties are important to address a child's milestone development and disease treatment throughout childhood. However, recognition of this sub-specialty has been slow, which has resulted in a global shortage of pediatric rheumatologists, and as a consequence, the demand for healthcare support far exceeds current service capacities. Raising awareness of this is important to attract more upcoming pediatricians into this rewarding area of healthcare.
==== Dissolved oxygen ==== Advanced microelectronics manufacturing processes require dissolved oxygen (DO) concentrations to be <10 μg/L in the ultrapure rinse water to prevent oxidation of wafer films and layers. DO in power plant water and steam must be controlled to ppb levels to minimize corrosion. Dissolved oxygen is measured by two basic technologies: electrochemical cell or optical fluorescence. Traditional electrochemical measurement uses a sensor with a gas-permeable membrane. Behind the membrane, electrodes immersed in an electrolyte develop an electric current directly proportional to the oxygen partial pressure of the sample. Optical fluorescent DO sensors use a light source, a fluorophore and an optical detector. The fluorophore is immersed in the sample. Light is directed at the fluorophore which absorbs energy and then re-emits light at a longer wavelength. The duration and intensity of the re-emitted light is related to the dissolved oxygen partial pressure by the Stern–Volmer relationship. The signal is temperature compensated for the solubility of oxygen in water and the fluorophore characteristics to obtain the DO concentration value.
Xi has pursued an assertive foreign policy, including toward China–United States relations, in the South China Sea, and along the Sino-Indian border dispute. He expanded China's economic and diplomatic presence in Africa and Eurasia through the Belt and Road Initiative. His 2015 meeting with Taiwanese president Ma Ying-jeou, the first between cross-strait leaders since the Chinese Civil War, was followed by deteriorating relations under the Democratic Progressive Party. He oversaw the enactment of the 2020 Hong Kong national security law, which effectively suppressed the city's pro-democracy camp. In 2018, Xi amended the constitution to remove presidential term limits and, upon his re-election in 2023, became the first Chinese president to serve more than two terms. Xi's ideology, known as Xi Jinping Thought, has been incorporated into the party and national constitutions.
Sources: en.wikipedia.org
Some opioid antagonists are not pure antagonists because they produce weak opioid partial agonist effects, and can produce analgesic effects when administered in high doses to individuals who have never taken opioids. Examples of such compounds include nalorphine and levallorphan. However, the analgesic effects from these specific drugs are limited and tend to be accompanied by dysphoria, most likely due to additional agonist action at the κ-opioid receptor. As they induce opioid withdrawal effects in people who are taking, or have recently used, opioid full agonists, these drugs are generally considered to be antagonists for practical purposes. The weak partial agonist effect can be useful for some purposes, and has previously been used for purposes such as long-term maintenance of former opioid addicts using nalorphine, however it can also have disadvantages such as worsening respiratory depression in patients who have overdosed on non-opioid sedatives such as alcohol or barbiturates. On the other hand, Naloxone has no partial agonist effects, and is in fact a partial inverse agonist at μ-opioid receptors, and so is the preferred antidote drug for treating opioid overdose. Naloxone and naltrexone are commonly used opioid antagonist drugs which are competitive antagonists that bind to the opioid receptors with higher affinity than agonists but do not activate the receptors. This effectively blocks the receptor, preventing the body from responding to opioids and endorphins. Naloxone is a drug used to treat opioid overdose.
== Discovery and ownership background == On 1 November 2005, Cambridge Antibody Technology (CAT) announced it was acquiring two anti-CD22 immunotoxin products from Genencor, namely GCR-3888 and GCR-8015. Genencor is the biotechnology division of Danisco and the acquisition meant CAT would hire certain former Genencor key employees to be responsible for the development of the programmes. GCR-3888 and GCR-8015 were discovered and initially developed by the National Cancer Institute, which is part of the U.S. National Institutes of Health. Genencor licensed the candidates for hematological malignancies and entered into a Cooperative Research and Development Agreement (CRADA) with the NIH, which will now be continued by CAT. Under the original license agreement with the NIH, CAT gained the rights to a portfolio of intellectual property associated with the programs and would pay future royalties to the NIH. CAT intended to file an Investigational New Drug (IND) application for GCR-8015 in various CD22 positive B-cell malignancies, including Non-Hodgkin lymphoma and chronic lymphocytic leukemia, following a period of manufacturing development which is expected to be complete by the end of 2006 and to support the NCI's ongoing development of GCR-3888 in Hairy cell leukemia (HCL) and pediatric acute lymphoblastic leukemia (pALL). CAT-8015 exhibited a greater affinity for CD22 than its predecessor, CAT-3888 and CAT's language such as "CAT will support the NCI's ongoing development of CAT-3888..." suggested at the time that their focus was on the second generation candidate.
== Further reading == ABARE (2000). National Plantation Inventory, March, 2000. 4p. Anon. (1997). Timber markets, home and away: Australian growers capitalising on international demand. Pie, Newsletter of Australia's International and National Primary Industries and Energy (PIE) R&D Organisations. Volume 7 (Summer Issue): p14. Avramidis et al. (2023). Basics of wood drying. link: [1] In: Springer Handbook of Wood Science and Technology Bootle, K.R. (1994). Wood in Australia: Types, Properties and Uses. McGraw-Hill Book Company, Sydney. 443p. Desch, H.E. and Dinwoodie, J.M. (1996). Timber: Structure, Properties, Conversion and Use. 7th ed. Macmillan Press Ltd., London. 306p. Doe, P.D., Oliver, A.R. and Booker, J.D. (1994). A Non-Linear Strain and Moisture Content Model of Variable Hardwood Drying Schedules. Proc. 4th IUFRO International Wood Drying Conference, Rotorua, New Zealand. 203-210pp. Haque, M.N. (1997). The Chemical Modification of Wood with Acetic Anhydride. MSc Dissertation. The University of Wales, Bangor, UK. 99p. Hoadley, R. Bruce (2000). Understanding Wood: A Craftsman's Guide to Wood Technology (2nd. ed.). Taunton Press. ISBN 1-56158-358-8. Innes, T. (1996). Improving Seasoned Hardwood Timber Quality with Particular Reference to Collapse. PhD Thesis. University of Tasmania, Australia. 172p. Keey, R.B., Langrish, T.A.G. and Walker, J.C.F. (2000). Kiln-Drying of Lumber. Springer, Berlin. 326p. Kollmann, F.F.P. and Cote, W.A.J. (1968). Principles of Wood Science and Technology. I. Solid Wood. Springer-Verlag, New York. 592p. Kumar, S. (1994).
Sources: en.wikipedia.org
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.
The compound is generally handled as light-sensitive and stored cold and dry. Stability in solution depends on solvent, concentration, and storage time. Specific degradation rates are not fully standardized.
Limited water solubility affects formulation for cell and animal studies. Organic co-solvents are often used to dissolve it. Precipitation can confound assay results if not controlled.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.